Specified Use-Results Study of ILARIS Solution for S.C. Injection (Schnitzler's Syndrome)
Status: Recruiting
Location: See all (5) locations...
Study Type: Observational
SUMMARY
The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• 1\. Patients diagnosed with Schnitzler's syndrome using canakinumab for the first time for the indication of Schnitzler's syndrome as described in the package insert.
• Patients starting treatment with canakinumab before conclusion of the contract for this study will also be included in the study so that all patients diagnosed with Schnitzler's syndrome who received canakinumab will be registered in this study.
Locations
Other Locations
Japan
Novartis Investigative Site
RECRUITING
Kanoya
Novartis Investigative Site
RECRUITING
Kobe
Novartis Investigative Site
RECRUITING
Osaka
Novartis Investigative Site
RECRUITING
Ushiku
Novartis Investigative Site
RECRUITING
Yokohama
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2026-05-13
Estimated Completion Date: 2032-11-25
Participants
Target number of participants: 10
Treatments
Canakinumab Cohort
Patients diagnosed with Schnitzler's syndrome using canakinumab for the first time.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals